Sgd Pharma
Sgd Pharma, headquartered in France, is a leading player in the pharmaceutical packaging industry, specialising in the design and manufacture of glass primary packaging solutions. Founded in 2002, the company has established a strong presence across Europe, Asia, and the Americas, catering to the diverse needs of the pharmaceutical and biotechnology sectors. With a commitment to quality and innovation, Sgd Pharma offers a comprehensive range of products, including vials, ampoules, and syringes, all designed to meet stringent regulatory standards. Their unique approach combines advanced manufacturing techniques with a focus on sustainability, positioning them as a trusted partner for global pharmaceutical companies. Notably, Sgd Pharma has achieved significant milestones in product development and market expansion, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Sgd Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Rubber and Plastic Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sgd Pharma's score of 38 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sgd Pharma's reported carbon emissions
In 2023, SGD Pharma reported total carbon emissions of approximately 203,584,000 kg CO2e for Scope 1 and about 199,732,000 kg CO2e for Scope 2, alongside 10,000,000 kg CO2e for Scope 3 emissions. This data reflects a commitment to transparency in their environmental impact, with emissions disclosed across all relevant scopes. SGD Pharma has set ambitious climate targets, aiming for a 35% reduction in Scope 1 and 2 emissions by 2030, compared to 2020 levels. Furthermore, the company plans to achieve a significant 65% reduction in these emissions by 2040. These targets are part of a broader strategy to align with climate goals, including a long-term objective of carbon neutrality by 2050. The company’s initiatives are focused on its plants located in France, Germany, India, and China, demonstrating a commitment to reducing its carbon footprint across its global operations. SGD Pharma's efforts are supported by its parent company, SGD S.A., which provides a framework for sustainability and emissions reduction. Overall, SGD Pharma is actively working towards reducing its carbon emissions while maintaining transparency and accountability in its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sgd Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
